Multicenter Study Using Proteomics, Microbiome, and Metabolomics to Predict Early Outcomes and Recurrence Risk in Adults with Acute Ischemic Stroke

What this Trial Is About

Researchers are investigating acute ischemic stroke AIS, a serious brain vascular disease with high rates of occurrence, recurrence, disability, and death, especially in China. This study focuses on the complex causes of AIS by analyzing changes in patients proteins, gut microbes, and metabolites to better predict prognosis and the risk of stroke coming back. By combining data from multiple molecular levels and using machine learning, they aim to develop early prediction models to improve patient care. The study collects blood and fecal samples from AIS patients across multiple centers to perform detailed proteomic, microbiome, and metabolomic testing. Patients are placed into groups called the modeling queue and validation queue to manage the development and evaluation of prediction models. This approach integrates experimental data and computational methods to identify key molecules and possible new targets for intervention, as well as to explore strategies for preventing stroke recurrence. Participants are followed for up to 12 months after their stroke, with assessments at 7 days, 3 months, and 12 months to track brain injury, vascular changes, neurological and cognitive function, daily living abilities, and emotional wellbeing. Researchers monitor the occurrence of new cardiovascular events and deaths within 12 months. The study involves collecting detailed medical histories, biological samples, and using standardized scales such as NIHSS, mRS, MMSE, MOCA, HAMD, and HAMA to evaluate patient outcomes and the predictive value of multi-omics data.

A Multicenter Study Based on Multi-omics Analysis to Predict the Early Prognosis and Recurrence Risk of Acute Ischemic Stroke